Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.

Frezza AM, Stacchiotti S, Gronchi A.

BMC Med. 2017 Jun 2;15(1):109. doi: 10.1186/s12916-017-0872-y. Review.

2.

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base.

Stelow EB, Bishop JA.

Head Neck Pathol. 2017 Mar;11(1):3-15. doi: 10.1007/s12105-017-0791-4. Epub 2017 Feb 28.

PMID:
28247233
3.

Oncogenic roles of SMARCB1/INI1 and its deficient tumors.

Kohashi K, Oda Y.

Cancer Sci. 2017 Apr;108(4):547-552. doi: 10.1111/cas.13173. Epub 2017 Apr 12. Review.

4.

Secondary EWSR1 gene abnormalities in SMARCB1-deficient tumors with 22q11-12 regional deletions: Potential pitfalls in interpreting EWSR1 FISH results.

Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, Antonescu CR.

Genes Chromosomes Cancer. 2016 Oct;55(10):767-76. doi: 10.1002/gcc.22376. Epub 2016 Jun 24.

5.

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.

Shen JK, Cote GM, Gao Y, Choy E, Mankin HJ, Hornicek FJ, Duan Z.

Sci Rep. 2016 Apr 29;6:25239. doi: 10.1038/srep25239.

6.

Gene of the month: SMARCB1.

Kalimuthu SN, Chetty R.

J Clin Pathol. 2016 Jun;69(6):484-9. doi: 10.1136/jclinpath-2016-203650. Epub 2016 Mar 3. Review.

7.

Newly Described Tumor Entities in Sinonasal Tract Pathology.

Bishop JA.

Head Neck Pathol. 2016 Mar;10(1):23-31. doi: 10.1007/s12105-016-0688-7. Epub 2016 Feb 1. Review.

8.
9.

SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.

Bishop JA, Antonescu CR, Westra WH.

Am J Surg Pathol. 2014 Sep;38(9):1282-9. doi: 10.1097/PAS.0000000000000285.

10.

Rhabdoid Variant of Myoepithelial Carcinoma, with EWSR1 Rearrangement: Expanding the Spectrum of EWSR1-Rearranged Myoepithelial Tumors.

Thway K, Bown N, Miah A, Turner R, Fisher C.

Head Neck Pathol. 2015 Jun;9(2):273-9. doi: 10.1007/s12105-014-0556-2. Epub 2014 Jul 4.

11.

Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology.

Agaram NP, Zhang L, Sung YS, Singer S, Antonescu CR.

Hum Pathol. 2014 May;45(5):1084-91. doi: 10.1016/j.humpath.2014.01.007. Epub 2014 Jan 28.

12.

Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas.

Yadav R, Sharma MC, Malgulwar PB, Pathak P, Sigamani E, Suri V, Sarkar C, Kumar A, Singh M, Sharma BS, Garg A, Bakhshi S, Faruq M.

Neuro Oncol. 2014 Mar;16(3):372-81. doi: 10.1093/neuonc/not228. Epub 2013 Dec 4.

13.

Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CW, Graus Porta D.

PLoS One. 2013 Oct 30;8(10):e77652. doi: 10.1371/journal.pone.0077652. eCollection 2013.

14.

Cutaneous syncytial myoepithelioma: clinicopathologic characterization in a series of 38 cases.

Jo VY, Antonescu CR, Zhang L, Dal Cin P, Hornick JL, Fletcher CD.

Am J Surg Pathol. 2013 May;37(5):710-8. doi: 10.1097/PAS.0b013e3182772bba.

15.

Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.

Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD.

Cancer Genet. 2012 Jul-Aug;205(7-8):391-404. doi: 10.1016/j.cancergen.2012.05.012.

16.

NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma.

Flucke U, Tops BB, Verdijk MA, van Cleef PJ, van Zwam PH, Slootweg PJ, Bovée JV, Riedl RG, Creytens DH, Suurmeijer AJ, Mentzel T.

Virchows Arch. 2012 Jun;460(6):621-8. doi: 10.1007/s00428-012-1240-0. Epub 2012 May 9.

17.

Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CW.

Cell Cycle. 2012 May 15;11(10):1956-65. doi: 10.4161/cc.20280. Epub 2012 May 15.

18.

p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.

Venneti S, Le P, Martinez D, Eaton KW, Shyam N, Jordan-Sciutto KL, Pawel B, Biegel JA, Judkins AR.

J Neuropathol Exp Neurol. 2011 Jul;70(7):596-609. doi: 10.1097/NEN.0b013e31822146ca.

19.

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.

Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, Roberts CW.

Cancer Res. 2009 Oct 15;69(20):8094-101. doi: 10.1158/0008-5472.CAN-09-0733. Epub 2009 Sep 29.

20.

SMARCB1/INI1 alterations and hepatoblastoma: another extrarenal rhabdoid tumor revealed?

Russo P, Biegel JA.

Pediatr Blood Cancer. 2009 Mar;52(3):312-3. doi: 10.1002/pbc.21893. No abstract available.

Supplemental Content

Support Center